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Abstract (143 words) 
 
Beyond sexual functions, androgens exert their action in skin physiology and 
pathophysiology. Skin cells are able to synthesize most of active androgens from gonadal 
or adrenal precursors and the enzymes involved in skin steroidogenesis are implicated both 
in normal or pathological processes. Even when the role of androgens and androgen 
receptor (AR) in skin pathologies has been studied for decades, their molecular 
mechanisms in skin disorders remain largely unknown. Here, we go over recent studies of 
androgens and AR roles in several skin-related disorders, focusing in the current 
understanding of its molecular mechanisms in androgenetic alopecia (AGA). We review on 
the molecular pathophysiology of type 2 5α-reductase, AR coactivators, the paracrine 
factors deregulated in dermal papilla (such as TGF-β, IGF 1, WNTs and DKK-1) and the 
crosstalk between AR and Wnt signaling in order to shed some light on new promising 
treatments. 
 
1-Introduction 
 
Steroid sex hormones play an essential role in the maintenance of normal function of 
reproductive organs and in the sexual dimorphism among other physiological and 
pathological functions in different body tissues. Androgens and estrogens are steroid 
hormones, mainly synthesized in adrenal glands, ovaries, testis, placenta and brain that act 
through specific intracellular receptors. Beyond sexual functions, they also exert many 
effects on skin in different physiological and pathological processes. 
The skin has the capability to produce androgens both de novo from cholesterol or using 
adrenal circulating precursors, such as dehydroepiandrosterone (DHEA), through specific 
enzymatic activities. Skin is a dynamic tissue that is renewed periodically, as well as is the 
hair follicle, which grows following a strict renewing cycle that is divided in defined 
phases. Androgens regulate many of these processes and others related to skin 
embryogenesis. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
3 
 
Androgen levels are under the control of enzymes catalyzing either its synthesis or 
destruction. These enzymes, as well as the binding to androgen receptor and coregulators, 
which are expressed in different skin regions in a specific spatial-temporal fashion, regulate 
androgen´s action.  
In this review, we resume the current knowledge regarding the androgen´s functions on the 
skin, primarily focused on the pilosebaceous unit.  
 
2-Role of androgens in skin physiology 
 
In the skin, androgens regulate hair growth, sebum production and secretion, among other 
physiological effects as wound healing and cutaneous barrier formation. 
Many long terminal hairs e.g. scalp hairs, eyelashes and eyebrows are developed from birth, 
maintained throughout life and have protective functions. Others hair types are secondary sexual 
characteristic and can be divided into two groups, adult axillar and pubic hairs in both sexes and 
beard and chest hairs in adult men [1-3]. They begin to growth to terminal hairs during puberty in 
response to the rise of plasma androgen levels [4, 5]. 
Sebum production by sebaceous glands is also under control of androgens. It was observed a 
significant rise in sebum production in both sex during the first days after birth, comparable to 
young adults, that is maintained until the second month of life, whereupon is observed a notably 
reduction [6]. This increase in sebum production correlates with the appearance of the so called 
genital crisis characterized by breast swelling, genital edema with hydrocele in boys and genital 
bleeding in girls that last two to three days. These results indicated that this sebum production rise 
would be related to androgen stimulation and correlated to the significant rise in plasma level of 
DHEA that is maintained through the first three month of life [7]. After the seventh year of life a 
new increase in DHEA secretion by adrenal glands (adrenarche) is observed in both sexes before 
any sign of puberty [7].  In this sense, it was observed a positive correlation of pre-pubertal acne, 
relative sebum secretion and urinary excretion of 17-ketosteroides in both sexes. Even though 17-
ketosteroids are weak steroids, the sebaceous glands can respond to their stimulus at this stage of 
development [8]. It was also demonstrated that dihydrotestosterone (DHT) stimulation is sufficient 
to induce commitment of functional AR-expressive immature sebocytes into lipogenic 
differentiation process [9]. After puberty, the sebum production in men is significantly increased 
and is greater in men than in age-matched women [10, 11], men suffering complete androgen 
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insensitivity [12] or castrated men. In this last study group, oral administration of methyl 
testosterone increased significantly sebum production [13]. 
The apocrine sweat glands of the human axilla produce odor substances with pheromone functions 
whose nature corresponds to volatile steroids [14-17]. These functions only begin with the puberty 
indicating that sex hormones stimulation is required [18]. Indeed, it has been suggested by ligand 
binding assays, the presence of intranuclear and cytosolic androgen receptors in apocrine sweat 
glands from patients with osmidrosis of both sexes [19]. Immunohistochemistry studies 
demonstrated strong expression of androgen receptor (AR) and estrogen receptor-β (ER-β) in the 
apocrine secretor epithelium [20]. AR showed a higher expression correlated to the height of 
epithelium [20]. These results agree with the fact that the low epithelium is considered resting or 
inactive and therefore the secretory activity would be regulated by androgen action through AR. 
Likewise, androgens upregulate many enzymes involved in cholesterol synthesis [21] and given the 
role of cholesterol as pheromone precursor, then androgen would have an important role in the 
synthesis and secretion of these volatile hormones. Likewise, DHT showed to increase expression 
of Apoprotein D (Apo D) in apocrine gland cells, a protein that play a carrier role for axillar odor 
molecules [22]. On the other hand, it has been observed that isolated human apocrine sweat glands 
showed high levels of 5α-reductase activity [23-25] and a higher concentration of DHT than 
testosterone in axillary skin from patients suffering osmidrosis [19]. These results suggested an 
anabolic activity of 5α-reductase in apocrine sweat glands like happens in sebaceous glands, 
supported by the fact of the predominance of 5α-reductase type 1 in this kind of glands [26]. 
The regulatory roles of androgens and estrogens in skin wound healing were already extensively 
reviewed [27, 28]. 
Androgen receptor (AR) is expressed in keratinocytes, inflammatory cells (mainly macrophages) 
and fibroblasts involved in wound healing process in C57BL/6 wild type male mice [29]. This 
expression of AR during early wound healing associated both to epithelization and inflammatory 
cellular infiltrate, would involve this receptor in inflammation and/or repair processes. Castration of 
these animals resulted in a more rapid cutaneous wound healing associated to a reduced 
inflammatory response, as it was pointed by the reduction of TNF-α expression at wounded tissue. 
Therefore, endogenous testosterone could be inhibiting wound healing by upregulating 
proinflammatory cytokines secreted by macrophages. Similar results were observed with flutamide 
treatment in non-castrated animals [29].  
Besides the effects on skin wound healing, androgens also demonstrated some role in cutaneous 
barrier formation [30]. Transepidermal water loss, as indicator of impaired barrier formation, was 
higher in male than female fetal rats and administration of the estrogen diethylstilbestrol to pregnant 
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mothers at estimated gestational day 14 to 16 accelerated fetal skin barrier development both 
morphologically and functionally. Otherwise dihydrotestosterone (DHT) delayed barrier fetal 
development when was administrated to pregnant mothers. Finally, the administration of AR 
antagonist flutamide in the same in vivo model avoided the gender differences in barrier formation. 
The effects of androgen on barrier homeostasis in both adult murine and human skin [31] were 
similar to what was exposed for fetal barrier formation. Hypogonadal mice showed faster skin 
barrier retrieval than normal animals and their treatment with testosterone displayed similar values 
to control. Similar results were observed in human hypopituitary patients treated with testosterone. 
The androgen mechanism underlying this effect appears to be related to epidermal lamellar body 
formation rather than differences in lipid synthesis [31].  
 
3 Steroidogenesis in the skin 
 
The synthesis of steroids hormones takes place in many tissues of which adrenal glands, ovaries, 
testis, placenta and brain are considered as classical steroidogenic organs. Nevertheless, skin 
constitutes an important peripheral steroidogenic tissue. Steroidogenesis pathway mainly focused in 
androgen synthesis is summarized in Figure 1 [32,33]. Human skin express key genes involved in 
the sex hormones synthesis such as CYP11A1, CYP17A1, 3β-hydroxysteroid dehydrogenase (3β-
HSD), CYP19A1 (aromatase) among others [34-36] suggesting that skin has all the synthesis 
machinery to produce androgens de novo (Figure 1).  
Although the skin can synthesize steroids de novo from cutaneous endogenous cholesterol, the main 
precursor used to produce steroids is adrenal DHEA-S. DHEA-S is hydrolyzed to DHEA by the 
steroid sulfatase located in sebaceous glands and dermal papilla cells (DPC) in terminal hair 
follicles [37, 38] whereas enzymatic activity of 3β-HSD1 converts DHEA into androstenedione, and 
17β-HSD3 converts androstenedione in testosterone [39]. 17β-HSD is present in 5 different 
isoforms that function as a switch on/off mechanism for the production of the most potent sexual 
steroids. The isotypes 17β-HSD3 and 5 catalyze production of testosterone from androstenedione, 
while isotypes 17β-HSD2 and 4 catalyze the opposite reaction oxydizing testosterone into weak 
androgen androstenedione [39] (Figure 1). Fresh plucked anagen hair follicle showed high level 
expression of 17β-HSD2 both at inner root sheath (IRS) and outer root sheath (ORS) keratinocytes 
[40]. Similar expression pattern was observed in sebaceous glands with a predominant expression of 
17β-HSD2 compared to the other isotypes probably by transcriptional regulation [41]. Moreover, a 
higher oxidative/reductive 17β-HSD ratio was seen in non-prone-acne skin compared to facial skin, 
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demonstrating a possible protective role of 17β-HSD in androgen effects on sebum over secretion 
[41]. 
Testosterone can be reduced to DHT by 5 α reductase enzyme. DHT is the most potent androgen 
for two reasons: 1) It cannot be aromatized to estrogen and 2) it has higher affinity for AR.  
The enzyme 5α-reductase presents three isotypes: 5α-reductase type 1, 2 and 3 [42, 43] (Figure 1). 
Type 1 is predominantly expressed in skin and annexes (sebaceous glands, sweat gland and hair 
follicles), type 2 is expressed in the epididymis, the seminal vesicles, prostate, genital fibroblasts 
[44-46]. Finally, type 3 has shown to be expressed both in benign and neoplastic prostate tissue, but 
overexpressed and more broadly distributed in advanced prostate cancer [47]. 
5α-reductase activity in human growing and resting hair follicles plucked from male scalp was first 
identified in 1972 by Takayasu [48]. A subsequent study showed that only 5-α reductase 1 inhibitor 
suppressed 5-α reductase 1 activity in plucked hairs, indicating that this enzyme corresponded to 
isozyme type 1[49]. Other authors have shown that both 5α-reductase 1 and 2 activity were found 
in dissected scalp hair follicles, with a higher expression in balding than occipital hair follicles [50]. 
Furthermore, DPC from beard showed in vitro, a higher 5α-reductase 2 activity than DPC from 
occipital hair [51, 52]. It was also reported that 5α-reductase 1 mRNA is expressed in all scalp hair 
follicle, whereas 5α-reductase 2 mRNA is only expressed in DPC or dermal shealth obtained from 
scalp hairs [53].  
In the same way, the pseudohermaphroditism consequence of 5α-reductase 2 deficiency, presented 
very strong evidence that beard hair growth and AGA hair loss could be related to activity of 5α-
reductase 2 and not to activity of 5α-reductase 1 [54]. The 5α-reductase activity in hair follicles is 
mainly located at DPC: this activity is 14 and 80-fold higher in DPC from scalp and beard 
respectively than the rest the of hair follicles [55]. Even if controversial reports have been 
published, most of the results seem to indicate that 5α-reductase 1 activity is ubiquitously 
distributed in hair follicles, whereas 5α-reductase 2 is located at DPC from beard and AGA hair 
follicles, pointing out the dermal papilla as an androgenic target. 
Testosterone can be converted into estrogens by aromatase action. Aromatase is encoded by 
CYP19, belongs to cytochrome P450 superfamily, and synthesizes estradiol (E2) and estrone (E1) 
from testosterone and androstenedione respectively (Figure 1). Aromatase is expressed in the ORS 
of anagen hair follicle and in sebaceous glands, but not in telogen hair follicles. Although, the 
expression was not uneven among body sites and gender, aromatase activity in women with AGA 
showed to be 2-fold higher in occipital compared to frontal hair follicles, and 6 to 3-fold higher in 
frontal and occipital sites, respectively, compared to men with AGA. Frontal follicles of women had 
almost twice aromatase activity than frontal hair follicles of men with AGA [50, 56]. Therefore 
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aromatase activity in the skin can serve as fine tune in the regulation of androgens and estrogens 
levels in target cells [57]. 
Given that DHT cannot be deviated to other non-androgenic pathway, it keeps its androgenic action 
unless it is degraded by another enzyme. This regulatory action is performed by 3α-HSD that 
catalyzes conversion of 5α-DHT into 3α-adiol (figure 1). This enzyme is mainly expressed in liver 
and regulates steroid hormone levels 
 
4- Androgen receptor in skin  
 
The action of androgens such as testosterone and DHT on skin is mainly mediated via the androgen 
receptor (AR), a ligand-dependent nuclear transcription factor and member of the steroid hormone 
nuclear receptor superfamily [58]. So, the lack of a functional AR results in severe alterations in the 
normal physiology of skin specially associated to development and physiology of skin appendages 
[59]). 
The AR gene is located in X chromosome as a single copy so that males are hemizygote, and 
inactivating mutations results in testicular feminization syndrome [60]. 
The AR consists of three basic functional domains: the N- terminal transcription regulation domain, 
the DNA binding domain (DBD) and the ligand binding domain.  
The N-terminal domain is the most variable, whilst the DBD is the most highly conserved region 
between the different members of the steroid hormone nuclear receptor family. Given the scarce 
variability between the DBDs, binding to selective androgen response elements (AREs) allows for 
the specific regulation of AR target genes [61]. The DBD is linked to the conserved ligand binding 
domain by a hinge region. The ligand binding domain allows physical association between the AR 
and heat shock proteins (HSP) in basal state. It also interacts with the N-terminus of the AR to 
stabilize bound androgens. Moreover, AR sequence includes: two transcriptional activating 
functions AF-1 and AF-2 [62, 63], a nuclear localization signal (NLS) and a nuclear export signal 
(NES) [64]. 
When AR interacts with its androgen ligand, it dissociates from HSPs, and the receptor-ligand 
complex translocates to nucleus and binds to AREs in the promoter region of androgen-regulated 
genes inducing their transcription in a DNA binding-dependent manner. On the other hand, 
androgens can exert their actions via the AR in a non-DNA binding-dependent manner, by initiating 
a rapid activation of second messenger signaling cascades. Moreover, ligand-independent actions of 
the AR have been identified recently (Reviewed in[65]).  
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Various coregulators can modulate AR function through binding to ligand binding domain or N-
terminal domain, and there are more than 200 AR coregulators identified including transcriptional 
factors, kinases, chaperones, cytoskeletal proteins, among others [66]. 
AR is ubiquitously expressed in the body and display diverse functions, either stimulating or 
inhibiting cell growth, in different target organs or tissues. Localization of AR was widely studied 
in the human skin and its appendages. AR is expressed in epidermal keratinocytes, dermal 
fibroblasts and vascular endothelial cells in both neonatal foreskin and skin from adult men and 
women [67]. In eccrine sweat glands, only few secretory cells were observed to express AR, but in 
sebaceous gland AR is detected in both basal cells and sebocytes.  
Most of latest works reported that in human hair follicle AR expression is restricted to DPC and is 
not found in the outer root sheath (ORS), hair bulb or bulge [68-72]. DPC derived from beard and 
balding scalp contain significantly greater levels of specific, low capacity, high affinity AR, as 
demonstrated with binding assays [73, 74], than those derived from relatively androgen-insensitive 
non-balding scalp follicles.  This fact would suggest that androgens act on hair follicles via the 
dermal papilla in vivo (reviewed in [75]. Nevertheless, its expression in the ORS and medulla is 
controversial. Interestingly, AR mRNA was found to be expressed in dermal and epithelial portions 
of microdissected hair follicles from scalp [53]. Moreover, the type I hair keratin hHa7 and the AR 
are co-expressed in the medulla of male and female sexual hairs, and the expression of hHa7 
appears to be directly regulated by androgens through three putative ARE motifs in its promoter 
[69]. Recently, the same group reported the in vitro androgenic regulation of this keratin in human 
occipital hair medulla, and a slight upregulation of AR expression in the nuclei of DPC and the cells 
of lower medulla of DHT-treated hair follicles [76].  
On the other hand, it was shown that TR3, an orphan member of the steroid/thyroid/retinoid nuclear 
receptor superfamily, is localized to the stem cell compartment in the human hair follicles. Besides, 
androgen increases TR3 expression in cultured keratinocytes, suggesting that TR3 mediates at least 
part of the inhibitory effect of androgens on keratinocytes [77]. 
 
5-Role of androgens in skin pathologies 
 
5.1 Acne vulgaris 
 
Acne vulgaris is a multifactorial human skin disorder that occurs at the level of the pilosebaceous 
unit and it is mainly observed on face, shoulders, chest and back. The involvement of androgens in 
acne pathogenesis is supported by many experimental and clinical evidences, listed below:  
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1) One of the best predictors of severe acne are serum levels of DHEA-S and the onset of acne 
correlates with increased DHEA-S levels during adrenarche [78],  
2) Severe acne observed in children suffering Congenital adrenal hyperplasia (CAH) [79] correlates 
with androgen excess due to the high levels of adrenocorticotrophic hormone (ACTH) induced by 
low cortisol levels.  
3) Absence of acne in men with androgen insensitivity or castration before puberty [80], 
4) Women with acne treated with antiandrogenic drugs reduced sebum production and improved 
mild to moderate acne [81, 82]. 
The major pathogenic factors involved in acne are infection by Propinobacterium Acnes which 
promotes perifollicular inflammation, hyperkeratinization that provokes obstruction of the 
infundibulum, stimulation of sebum production, seborrhea and excessive presence of androgens 
from local or systemic origin [83-86]. The activation of innate immunity begins with the interaction 
of surface proteins from Propinobacterium Acne with Toll Like Receptor-2 (TLR-2) present in 
sebocytes, keratinocytes and monocytes, inducing proinflammatory cytokines expression [87-90]. 
Moreover, DHT has been shown to be involved not only in sebum production but also in 
proinflammatory cytokine secretion by sebocytes [91]. 
A greater reductive activity of 17β-HSD indicative of a higher testosterone synthesis, was observed 
in sebaceous glands from acne-prone areas like facial skin, compared to non-acne-prone areas 
[41].Precisely,  17β-HSD 3 and 5 isozymes that catalyze the reduction of androstenedione to 
testosterone are preferentially expressed at sebaceous glands located in facial skin [36] (Figure 1). It 
is also interesting to note that the aromatase inhibitor MPV-2213 showed to produce acne as an 
adverse effect,  suggesting the involvement of aromatase activity in the control of testosterone level 
associated to acne pathophysiology [92]. 
 
5.2 Hidradenitis suppurativa 
 
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease of the hair follicle affecting 
apocrine gland-bearing areas like axillary, inguinal and anogenital regions [93]. Exacerbation of HS 
in women was associated with menstruation (period normally characterized by low estrogen levels) 
and luteal phase of menstrual cycle (boost in ovarian androgens) indicating certain role of 
androgens in the pathogenesis of the disease [94, 95]. HS patients present normal androgens levels 
in serum suggesting that increased peripheral conversion of androgens rather than circulating levels 
could be involved in HA pathogenesis [94]. Nevertheless, in other studies, 5α-reductase enzyme 
that produces DHT from testosterone, and proposed as a pivotal factor in HS, showed similar levels 
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both in patients and healthy controls [25]. Neither androgen nor estrogen receptor expression 
showed differences between patients and healthy controls [96]. Beyond these results indicating the 
lack of association between androgen and/or AR with HA there exist reports showing illness 
improve after antiandrogen treatments [97, 98]. 
 
5.3 Androgenetic alopecia 
 
The relationship between male gender condition and alopecia was suspected since very early human 
history. In 40’ decade of the past century, Hamilton et al [99] showed that androgen stimulation is a 
prerequisite for common or androgenetic alopecia (AGA). Thus, androgens effects on human hair 
growth regulation vary depending on body sites. Even if androgens normally stimulate hair 
production in many sites of the body (e.g., the beard and the axillary regions), they can exert an 
opposite effect to suppress hair growth on genetically predisposed frontal and vertex scalp [100].  
AGA is the most common form of hair loss in humans. AGA is caused by vellus transformation of 
scalp hairs, which corresponds to hair follicle miniaturization by repeated hair cycles with shortened 
anagen phase. AGA may begin during puberty and the prevalence rates in Caucasian population is 
approximately 50% among men between 40 – 49 years old  and by the age of 80, over 90% of 
Caucasian men are affected to a various degree [101]. 
The important role of androgens and genetic factors in AGA has been confirmed. Hamilton [99] 
first demonstrated that this process is mediated mainly by androgen based on his clinical 
observation of androgen induction of AGA in men with testicular insufficiency. He also observed 
that eunuchoid and prepubertally castrated men do not develop baldness and had a reduced sebum 
secretion in areas which normally showed abundant sebum as happen in adult man facial skin and 
hairs [99]. Testosterone administration to these patients resulted in restoration of normal male 
developing scalp baldness and increased sebum secretion, demonstrating the importance of genetic 
factors in AGA indicating a close relationship between androgens and these two phenomena.  
In males, AGA is characterized by a distinct pattern of androgen-dependent progressive hair loss 
from the scalp (male-pattern alopecia) that starts with a bi-temporal recession of the frontal hair line 
and follows by a thinning of the frontal and vertex scalp areas. This process eventually leads to 
complete baldness of the top of the scalp.  
The prevalence of AGA among women is lower than in men [102]. As female scalp hair loss is 
clinically, etiologically and genetically different from the male baldness in many features [103], it is 
now designated as Female Pattern Hair Loss (FPHL).  FPHL results from a progressive decrease in 
the ratio of terminal hairs to shorter, thinner vellus hairs. This follicular miniaturization is typically 
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presented as a diffuse reduction in hair density over the frontal and vertex areas, but parietal and 
occipital regions may be involved [104]. The mechanism through which this follicular 
transformation occurs in FPHL is not completely understood. Even if the roles of androgens and 
genetic susceptibility in male AGA are well accepted, the degree to which these factors contribute 
to FPHL is less clear [103]. In both men and women a higher expression of 5α-reductase 1 and 2 in 
frontal than in occipital hair follicles was observed; but in men its expression was approximately 3-
fold higher than in women [50]. Estrogens may prolong hair follicle anagen growth phase [57, 105]. 
Moreover estradiol inhibits hair shaft growth in occipital hair follicles in women whereas stimulates 
frontal hair growth in men [106, 107] and 17α-estradiol stimulates aromatase activity in women hair 
follicles [108]. Therefore the conversion of androgen into estradiol by aromatase activity could be a 
regulatory mechanism to control androgen activity in hair follicles (Figure 1).  
Men suffering AGA have normal levels of circulating androgens. However, testosterone and DHT 
can be synthesized in the pilosebaceous unit [36, 109, 110]through mechanisms that include one or 
more enzymes (Figure 1). The unwanted androgen metabolism at the hair follicle is the major factor 
involved in the pathogenesis of AGA. Elevated activity of 5α-reductase 2, which metabolizes 
circulating testicular testosterone into DHT in the genetically predisposed temporal and vertex 
follicles, is the most significant factor in men. The important role of 5α-reductase in AGA is 
supported by the absence of temporal regression and baldness in cases of 5α-reductase deficiency 
[111, 112].  
3β-HSD activity in AGA patients is higher in frontal scalp hair follicles than in occipital scalp hair 
follicles [113]. Decreased aromatase activity (the enzyme that converts circulating ovarian 
testosterone into 17 beta-estradiol) leading to elevated local concentration of testosterone seems to 
be operative in women [114].  
As no correlation between pattern of baldness and serum androgen has been found [115], the 
pathogenic action of androgens is likely to be mediated through the intracellular signaling of hair 
follicle target cells.  
 
5.3.1 Androgen receptor in AGA 
 
As mentioned before androgens/AR actions are involved in regulation of normal skin development 
and function as well as in some skin pathological events, as AGA.  
DPC from androgen-sensitive follicles (beard, axilla, pubis and vertex/balding scalp) contained 
higher levels of AR than those derived from relatively androgen-insensitive non-balding occipital 
scalp follicles [68, 116-120], showing that DPC exhibit an altered phenotype in culture which 
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depends on the body site from which they were derived.  As hair follicles from temporal and vertex 
areas of the scalp express large quantities of AR, binding of increased local levels of DHT is 
favoured, causing the shortening of anagen phase and progressive miniaturization of thick, 
pigmented terminal hair into thinner and  non-pigmented vellus-like hair. 
Normal testosterone levels are frequently observed in women with androgenetic alopecia (AGA), 
suggesting the involvement of androgen sensitivity in this condition. It was recently reported the 
increased AR messenger RNA expression in frontal-parietal hair follicles of women with AGA 
compared to controls [121]  confirming the relation between androgen sensitivity and the AR 
mRNA production. Moreover, AR content in female frontal hair follicles is approximately 40% 
lower than in male counterparts. This difference may account for the particular clinical presentation 
of AGA in women and men [50]. 
 
5.3.1.1 Senescence in AGA 
In an effort to elucidate the mechanisms implicated in the pathogenesis of AGA, a recent study 
indicated that balding DPCs undergo premature senescence in vitro denoted by senescence-
associated β-galactosidase (SA β-gal) and p16INK4a protein expression, and markers of oxidative 
and DNA damage [122]. In the same line, it was reported that androgen/AR signaling accelerates 
premature senescence of human DPCs from frontal scalp, in association with DNA damage [123]. 
This fact is thought to reflect the irreversible cell growth arrest and may explain the miniaturization 
of hair follicles observed in AGA patients. 
 
5.3.1.2 AR polymorphisms in AGA 
 
The AR gene has three common polymorphisms. The two most important, CAG and GGN 
trinucleotide repeats in AR exon1, have been shown to be associated with prostate cancer risk [124-
126]. They represent interesting AR activity markers because particular repeats alleles are 
associated with higher protein level or increased transactivity function [Ding, D 2004]. These 
polymorphisms were also associated with androgen-dependent skin disorders, but the overall results 
are still controversial. There are positive associations between shorter repeats alleles and skin 
disorders. CAG trinucleotide shorter repeats were shown to be related with acne, hirsutism and 
AGA [127-129] and patients with greater androgen sensitivity (<24 CAG repeats) were likely to 
have a significant response to finasteride treatment either in male  [130]or female  [131]  AGA. 
However, other study showed that only GGN equally or less than 23 trinucleotide repeat alleles are 
truly associated with AGA [132]. Since both polymorphisms modulate AR activity, but only GGC 
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repeats showed to be associated with AGA, it is possible that cells from hair follicle lack certain 
cofactors that interact with CAG repeats. Taken together these results indicate that the main 
baldness factor is inherited from maternal family branch through X chromosome. Nevertheless, 
other genetic factors located at autosomal loci also could modulate AR functions and explain the 
similarity in AGA pattern observed in fathers and sons. 
The third common polymorphism in the AR gene, is a StuI restriction-site polymorphism (E211 
G>A). The E211 A allele is associated with a decreased risk of metastatic prostate cancer and 
androgenetic alopecia [133]. 
A meta-analysis from published data was recently conducted to determine whether the common AR 
gene polymorphisms confer susceptibility to AGA. These reviewers suggest that the G allele of AR 
StuI polymorphism might be a potential risk factor for AGA, especially in white populations. 
However, they did not find any obvious association between the CAG or GGC repeats 
polymorphisms of the AR gene and the risk for AGA [134]. 
 
5.3.1.3 AR methylation in AGA 
The AR gene includes a ∼1.5Kb CpG island encompassing the transcription start site and exon1. 
Differential methylation patterns have been linked with differential AR expression in various 
prostate cancer cell lines [135, 136]. 
AR gene promoter methylation is higher in occipital scalp hair follicles compared with those from 
vertex AGA scalp, pointing it as a mechanism that may influence the AR expression in hair follicle. 
AR promoter methylation may protect occipital hairs from miniaturization and hair loss [137]. 
Interestingly, it was recently demonstrated that DNA methylation regulates AR expression in 
developing prostate. This process may be a novel mechanism that controls androgen sensitivity and 
timing of mouse prostate ductal development. The authors propose that AR DNA methylation could 
represent a novel developmental checkpoint [138]. 
 
5.3.2 AR Coregulators in AGA  
 
As mentioned above, DHT strongly binds to AR located in the cytoplasm of the target cells and the 
AR-DHT complex is translocated to the nucleus after dimerization. The interaction of the AR-DHT 
complex with the androgen responsive element (ARE) is modulated by a variety of proteins called 
coregulators. These AR coregulators are classified as coactivators when they activate transcription 
mediated by the AR or as corepressors when they suppress it [139].  
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Although many androgen receptor coactivators have been identified [61], their physiological and 
pathological significance is still not fully understood. It seems that the presence of different 
coregulators provides tissue specificity of androgen-elicited responses. Coregulators add another 
factor to the complexity of androgenic action on hair and could be involved in its paradoxical effect 
on scalp hair. A differential expression pattern of an AR coactivator in human hair follicles was first 
described by Lee et al. [140] suggesting its possible role in AGA. This study has shown a reduction 
of ARA70b/ELE1b expression in the dermal papilla and the hair bulbs from balding hairs. As 
ARA70b/ELE1b promotes cell growth [141], it is likely that this decrease of ARA70b/ELE1b 
contributes to the retardation of hair follicle growth and eventually leads to hair follicle 
miniaturization, major characteristics of AGA.   
Another AR coactivator, Hic-5/ARA55 was found as a molecular regulator of androgen sensitivity 
in human hair follicle.  It is highly expressed in DPC of hair follicles from androgen-sensitive sites 
such as AGA and beard, suggesting that Hic-5/ARA55 can enhance androgen sensitivity in dermal 
papilla [142]. The levels of Hic-5/ARA55 were found to correlate with previously reported levels of 
the androgen receptor in DPC from various sites [120, 143, 144].  
These reports indicate that selective AR coactivators may be involved in the pathogenesis of AGA 
and therapeutic strategies targeting the action of coregulators might have an application in scalp hair 
loss. 
Summarizing altogether the findings exposed above suggest that the sensitivity of hair follicles to 
androgens is mainly regulated through the 5α-reductase enzyme, AR, and AR co-activators. 
 
5.3.3 Deregulation of DPC secreted factors  
 
The observation that DPC derived from androgen sensitive sites (e.g., beard and frontal scalp) 
contain low capacity, high affinity AR[120] suggests that these cells are the main site of androgen 
action in the hair follicles. Embryonic induction of hair follicles and their regeneration during 
cycling is a process that implicates a crosstalk between epithelial precursor cells and the underlying 
mesenchymal dermal papilla, possibly through paracrine mediators [145]. These secreted factors 
from the DPC cause epithelial cells to proliferate and differentiate into the hair follicle cell lineages 
to produce the hair shaft [146, 147]. Androgen-driven alteration of the autocrine and paracrine 
regulatory factors produced by scalp DPC that influence self-growth or the growth of epithelial 
follicular components may be a key to AGA development. Researchers have been focused on 
identifying androgen-regulated factors and the signaling pathways involved in this crosstalk at 
different hair cycle stages. Many of them have been reported [147, 148]. 
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Androgens were found to stimulate the synthesis and secretion of TGF-β from the dermal papilla 
isolated from the bald scalp, and this peptide factor may be responsible for androgen-induced 
growth inhibition in cocultured epithelial cells [75]. Both TGF-β1[149, 150], and TGF-β2 [151] 
have been identified as androgen-inducible negative mediators for AGA development . 
IGF-1 was first identified as a testosterone-inducible positive paracrine mediator from beard DPC 
[68] that  induced follicular epithelial cell growth using a coculture system of ORS cells and beard 
DPC. In addition, testosterone also induced autocrine stimulatory factors from beard DPC [152], 
which suggests that autocrine behavior is also involved in androgen regulation for beard growth 
IL-6 was reported as upregulated in balding DPC compared with non-balding DPC and DHT-
inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and 
promoting regression of hair follicles[153]. 
Moreover, the finding that DHT increases inducible nitric oxide (NO) synthase (iNOS) from DPC 
suggests that iNOS and NO are downstream effectors of AR in DPC [154].  
Other reported findings that stem cell factor (SCF) is produced in higher amounts by beard than 
scalp DPC [155], and balding DPC produce less SCF than non-balding scalp DPC [156] 
presumably in response to androgens in vivo. Because SCF is the ligand for the cell surface 
receptor, c-kit, found on human follicular melanocytes, this may play a role in androgen-potentiated 
changes in hair pigmentation. In AGA, miniaturized hairs are paler than normal scalp hairs, 
however the concentration of melanocytes per unit area of the hair bulb does not change and they 
retain the same levels of the c-kit receptor protein. The reduced SCF production by balding DPC 
was the only detected difference. 
Other diffusible factors that modulate papilla–epithelium interaction do exist, which include the 
Wnt (wingless-type MMTV integration site family) proteins [157]. The expression of the Wnt 
ligand antagonist dickkopf1 (DKK-1) has been found to be upregulated in response to DHT and 
reported to cause apoptosis in follicular keratinocytes co-cultured with DPC. Moreover, DKK-1 
expression level is also elevated in the bald scalp of patients with AGA [158] . 
 
5.3.4 Crosstalk between androgen and Wnt/β-catenin signaling in AGA 
 
Hair follicle regeneration begins when signals from the mesenchyme derived DPC reach 
multipotent epidermal stem cells in the bulge region. Activation of the Wnt ⁄β-catenin signalling 
pathway is important for the initiation and maintenance of hair morphogenesis [145, 159] and is 
critical for the maintenance of DPC inductive properties required for hair follicle regeneration and 
growth of the hair shaft [160-162]. The activation of Wnt signaling, especially Wnt10b is essential 
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for hair follicle development, hair cycling and hair growth [163]. Besides, the maintenance and 
growth of those hair follicles needs subsequent interaction of Wnt pathways between dermal and 
epidermal cells [161].  
The importance of the Wnt/β-catenin pathway in AGA is emphasized by the demonstration of 
molecular cross-talk between androgens and the Wnt signaling in DPC. It was observed that in DPC 
from patients with AGA, the Wnt ⁄β-catenin signaling pathway is negatively influenced by ligand-
activated AR. Hacat keratinocyte proliferation and Lef/Tcf-mediated transcriptional activity 
stimulated by Wnt-3a were suppressed by DHT in a coculture of Hacat and DPC from AGA [157]. 
However, these phenomena could not be observed in DPC of non-AGA males. Moreover, we 
demonstrated that androgens regulate secreted factors involved in normal HF stem cell 
differentiation via the inhibition of the canonical Wnt signalling system in androgen-sensitive DPC 
[164]. We provided evidence that androgen activation of glycogen synthase kinase-3β (GSK-3β) 
appears to be responsible for the inhibition of Wnt ⁄β-catenin signaling in androgen-sensitive DPC 
(Figure 2).  Further studies will be necessary to elucidate the mechanism involved in the GSK-3β 
dephosphorylation mediated by androgens. In accordance with our findings, it has been reported 
previously that treatment of human DPC with a GSK-3β inhibitor resulted in an increased activity 
and expression of indicators of hair inductivity [165]. A functional cross-talk between the AR and 
Wnt signaling pathways has been described in target tissues [166]. It is becoming more evident that 
androgens deregulate DPC-secreted factors involved in normal HF stem cell differentiation via the 
inhibition of the canonical Wnt signaling pathway. Thus, the identification of these DPC-secreted 
factors would contribute to elucidating the regulation of epithelial–mesenchymal interactions that 
occur at the onset of hair regeneration and will lead to further understanding of the differentiation 
defects of hair follicle stem cells (HFSC) during AGA development. The observation that stem cells 
number was maintained in bald scalp whereas progenitor cells were markedly diminished supports 
this notion [167]. Understanding the signals responsible for stem cells differentiation would be the 
next step in developing new treatments for AGA. We have recently reported the role of Wnt 
agonists/antagonists as mediators of androgen inhibition of DPC-induced HFSC differentiation 
[168]. Wnt agonists/antagonists balance was analyzed after DHT stimulation of androgen-sensitive 
DPC and a downregulation of Wnt5a and Wnt10b was found while the Wnt antagonist Dkk-1 was 
upregulated. In addition, DKK-1 impaired HFSC differentiation mimicking androgens' action while 
the addition of WNT10b to DPC-medium conditioned with DHT, overcame androgen inhibition of 
HFSC differentiation. Our results identify DKK1 and WNT10b as paracrine factors which modulate 
the HFSC differentiation inhibition involved in androgen-driven balding (Figure 2) 
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The identification of more factors secreted by DPC responsible for differentiation of HFSC would 
contribute to elucidating the regulation of epithelial-mesenchymal interactions that occur at the 
onset of hair regeneration. It will lead to further understanding of the mechanisms involved in AGA 
development; thus opening a new option of targeted treatments for AGA through the modulation of 
the Wnt/β-catenin pathway. 
There are already some studies showing that drugs that can act by activating Wnt signaling may be 
useful. Valproic acid (VPA), which activates the Wnt/β-catenin pathway and inhibitors of GSK-3β 
like lithium chloride and beryllium chloride, have been shown to induce hair regrowth through 
induction of anagen in murine model [169]  and promote human hair growth in a phase II clinical 
trial that compared topical VPA (8.3 % sodium valproate) versus placebo for 24 weeks in 27 men 
with moderate AGA [170].  
Another phase I trial revealed increased hair shaft thickness, hair density and number of total 
terminal hair without any significant adverse effects, compared with placebo at 12 weeks in subjects 
with AGA after intradermal administration of a ‘Hair Stimulating Complex’(HSC). HSC is a 
bioengineered, non-recombinant, human cell-derived formulation containing Wnt7a protein, 
epidermal growth factors, and follistatin [171]. No relevant adverse effects were observed and 
phase II of this study is currently in progress with any published result available.  
One more molecule that activates the Wnt pathway—SM04554— showed in a phase I clinical trial, 
to be safe, well-tolerated, and potentially efficacious for AGA treatment. According to a company 
report, in phase II trials the SM04554 topical solution (0.15 and 0.25 %) produced a statistically 
significant increase for both objective outcome measures: non-vellus hair count and hair density 
[172].  
 
6- Conclusions and perspectives 
 
The involvement of androgens and AR in many of the skin pathologies is well known and has been 
studied for decades; however, the molecular mechanisms by which androgens get involved in these 
skin disorders remain largely unknown. 
Evidence has emerged of several other factors and processes which are able to contribute to the AR 
function.  
The progressive elucidation of  the distinct roles of androgens and AR or its downstream pathways 
in each skin disease is contributing  to the development of better therapies that can specifically 
target AR (instead of androgens) to treat these disorders. Treatments targeting androgen metabolism 
in prostate cancer often result in undesirable side effects that are not acceptable in skin disorders, 
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taking into account the benefits they would cause to patients. The crucial aim in these androgenic 
skin disorders is to attenuate the pathological conditions more effectively, reducing side effects. A 
good approach to minimize the side effects is to develop topical reagents which could be efficiently 
delivered into the skin target cells and degraded before entering the circulation system.  
In the case of the Androgenetic alopecia (AGA), the current understanding of the molecular 
mechanisms in androgen signaling pathway such as type 2 5α-reductase, AR, its coactivators, the 
deregulated  paracrine mediators from dermal papilla (such as TGF-β, IGF 1, WNTs   and DKK-1 ) 
and the crosstalk  between AR and Wnt signaling pathways has opened the possibility of novel 
therapies.  These new investigational treatments promise not only to stimulate hair growth, but also 
to induce formation of new hair follicles using bioengineering approaches and multiplication. 
Moreover, even if more studies are needed to prove their efficacy, new treatments targeting the Wnt 
signaling and others using stem cells have also shown to have a positive effect on hair regrowth. 
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FIGURE LEGENDS 
 
Figure 1. Steroidogenesis pathway focused in androgen synthesis and the regulation of 
androgen levels by different enzymes isotypes involved in this pathway. 
 
Figure 2. Crosstalk between androgens and Wnt/β-catenin signaling in DPC. Effects on HFSC 
differentiation. Black dashed line denote activation of Wnt/ β-catenin signaling in DPC and 
subsequent epithelial–mesenchymal Wnt pathways interactions, essential for hair growth and 
maintenance of hair follicles. Gray continuous line represent androgen signaling activation in 
sensitive DPC (p.e. from AGA patients), favouring the active form of glycogen synthase kinase-3β 
(GSK-3β) and consequent inhibition of Wnt ⁄β-catenin signaling (preventing LEF/TCF mediated 
gene transcription). Androgen/AR complex binding to AREs containing promoters of target genes 
disrupts Wnt agonists/antagonists (p.e.WNT10b; DKK1) balance involved in normal HFSC 
differentiation and in DPC inductive ability. 
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Highlights 
Androgens have physiological and pathological effects on skin. 
Skin has the enzymes necessary to synthesize androgens di novo or from precursors. 
The enzymes regulate the level of the most potent androgens, testosterone and DHT. 
Crosstalk between androgen and Wnt signalling in DPC influences progression of AGA. 
DHT blocks normal HFSC differentiation deregulating DPC-secreted factors. 
